Fingolimod effect on disability progression in primary progressive multiple sclerosis patients with inflammatory activity: A post-hoc subgroup analysis of the INFORMS study

被引：0
|
作者：
Wolinsky, J. S. [1 ]
Cree, B. A. C. [2 ]
Freedman, M. S. [3 ]
Hartung, H. -P. [4 ]
Lublin, F. [5 ]
Miller, D. H. [6 ]
Montalban, X. [7 ]
Uitdehaag, B. [8 ]
Weiner, H. [9 ]
Lubetzki, C. [10 ]
Putzki, N. [11 ]
Li, B. [12 ]
Haring, D. A. [11 ]
Merschhemke, M. [11 ]
Kappos, L. [13 ]
机构：
[1] Texas Hlth Sci Ctr, Houston, TX USA
[2] Univ Calif San Francisco, Multiple Sclerosis Ctr, San Francisco, CA 94143 USA
[3] Univ Ottawa, Ottawa Hosp Res Inst, Ottawa, ON, Canada
[4] Heinrich Heine Univ, Med Fac, Dusseldorf, Germany
[5] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[6] UCL Inst Neurol, Queen Sq MS Ctr, London, England
[7] Hosp San Pedro Univ Vall dHebron, Barcelina, Spain
[8] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands
[9] Harvard Med Sch, Brigham & Womens Hosp, Boston, MA USA
[10] Univ Paris 06, Salpetriere Hosp, Paris, France
[11] Novartis Pharma AG, Basel, Switzerland
[12] Novartis Pharmaceut, E Hanover, NJ USA
[13] Univ Basel, Univ Hosp, Basel, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷
基金：
新加坡国家研究基金会; 美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P1283
引用
收藏
页码：679 / 680
页数：2
相关论文
共 50 条
  • [31] Sustained reduction in confirmed disability progression after 6.5 study-years of ocrelizumab treatment in patients with primary progressive multiple sclerosis
    Wolinsky, J. S.
    Brochet, B.
    Hartung, H. P.
    Naismith, R. T.
    Airas, L.
    Coutant, K.
    Koendgen, H.
    Manfrini, M.
    Mehta, L.
    Prajapati, K.
    Kappos, L.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [32] Effect of Siponimod on Cognition in Patients with Secondary Progressive Multiple Sclerosis (SPMS): Phase 3 EXPAND Study Subgroup Analysis
    Benedict, Ralph
    Fox, Robert
    Tomic, Davorka
    Cree, Bruce
    Vermersch, Patrick
    Giovannoni, Gavin
    Bar-Or, Amit
    Gold, Ralf
    Ritter, Shannon
    Karlsson, Goeril
    Wolf, Christian
    Kappos, Ludwig
    NEUROLOGY, 2019, 92 (15)
  • [33] Risk reduction of EDSS progression in patients with relapsing multiple sclerosis treated with cladribine tablets in the CLARITY study: post-hoc analysis including patients who went on to receive rescue therapy
    Thrower, B.
    Fox, E. J.
    Damian, D.
    Lebson, L.
    Dangond, F.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 306 - 307
  • [34] Efficacy and safety of delayed-release dimethyl fumarate in treatment-naive Japanese patients with relapsing-remitting multiple sclerosis: A post-hoc subgroup analysis of the apex study
    Mori, M.
    Ohashi, T.
    Onizuka, Y.
    Hiramatsu, K.
    Hase, M.
    Yun, J.
    Ling, Y.
    Torii, S.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2017, 381 : 795 - 796
  • [35] Effect of Age on the Safety and Efficacy of Selinexor in Patients with Relapsed Refractory Multiple Myeloma: A Post-hoc Analysis of the STORM Study
    Gavriatopoulou, Maria
    Vogl, Dan T.
    Nooka, Ajay
    Dingli, David
    Cole, Craig
    Moreau, Philippe
    Huff, Carol
    Yee, Andrew
    Dimopoulos, Meletios A.
    Lonial, Sagar
    Richardson, Paul G.
    Stewart, Keith
    Chari, Ajai
    Richter, Joshua
    Biran, Noa
    Siegel, David S.
    Liu, Jianjun
    Joshi, Anita
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael
    Jagannath, Sundar
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (10): : E117 - E118
  • [36] Effect of ofatumumab treatment on disability progression independent of relapse activity in patients with relapsing multiple sclerosis
    Kappos, L.
    Montalban, X.
    Cohen, J. A.
    Comi, G.
    Coyle, P. K.
    Li, B.
    Sfikas, N.
    Willi, R.
    Haring, D. A.
    Merschhemke, M.
    Hauser, S. L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2020, 27 : 47 - 47
  • [37] Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis
    Perez-Miralles, F.
    Prefasi, D.
    Garcia-Merino, A.
    Gascon, F.
    Medrano, N.
    Castillo, J.
    Cubas, L.
    Alcala-Vicente, C.
    Gil-Perotin, S.
    Casanova, B.
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 : 188 - 188
  • [38] A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis
    Abe, Koji
    Itoyarna, Yasuto
    Tsuji, Shoji
    Sobue, Gen
    Aoki, Masashi
    Doyu, Manabu
    Hamada, Chikuma
    Togo, Masanori
    Yoneoka, Takatomo
    Tanaka, Masahiko
    Akimotot, Makoto
    Nakamura, Kazue
    Takahashi, Fumihiro
    Kondo, Kazuoki
    Yoshino, Hiide
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2017, 18 : 11 - 19
  • [39] An exploratory analysis of 12-and 24-week composite confirmed disability progression in patients with primary progressive multiple sclerosis in the ORATORIO trial
    Giovannoni, G.
    Arnold, D. L.
    Bar-Or, A.
    De Seze, J.
    Hemmer, B.
    Montalban, X.
    Rammohan, K. W.
    Belachew, S.
    Bernasconi, C.
    Chin, P.
    Garren, H.
    Masterman, D.
    Sauter, A.
    Wei, W.
    Wolinsky, J.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 371 - 372
  • [40] Disability Improvement And Progression As Assessed By The Multiple Sclerosis Functional Composite In Progressive MS Patients From The Climb Study
    McAdams, M. T.
    Rosso, M.
    Healy, B. C.
    Yano, H.
    Glanz, B.
    Kern, R.
    Ward, S. E.
    Mehra, M.
    Weiner, H.
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (1_SUPPL) : 150 - 151
12345